I wanted to provide a brief update on several important milestones for entX as we continue to progress key programs across healthcare, space and defence.

As you may have seen, recent national media coverage has highlighted entX as a leader in Australian next-generation nuclear battery technology for space and defence applications. Our GenX program is now progressing toward pre-commercial manufacture over the next 12 months, marking an important step in the commercialisation pathway.

This recognition is an encouraging endorsement of our strategy and is helping build awareness with key industry and government stakeholders.

Read the article from The Australian.

And for anyone wondering about the listed company reference in the article - no, you haven’t missed anything. entX remains unlisted as we continue focusing on building long-term value before ringing any bells.

In parallel, our “Mines to Medicine” strategy is now moving from concept to execution. entX has successfully taken delivery of its first Radium-228 (Ra-228) shipment produced in collaboration with ANSTO. This milestone demonstrates that the upstream production process is working at scale and secures a critical isotope for future alpha-emitting radiopharmaceutical applications alongside our long-term supply arrangements.

Read the full media release.

Building on this momentum, the recent IsoMedica / entX Investor Webinars outlined a clear near-term roadmap:

• IsoMedica targeting initial revenues in Q4 2026

• The GenX nuclear battery program advancing toward commercialisation

• Our RHU program tracking toward flight heritage later this year.

Watch the latest webinar featuring Chief Scientific Officer, Massey de los Reyes, on our website.

Stay tuned for our next webinar on Space and Defense: GenX.

Collectively, these developments reinforce that entX is now firmly in an execution phase, with multiple value-creating milestones ahead across healthcare, space and defence.

Thank you for your ongoing support as we continue to build momentum across the business.

Kind regards,

Bryn Jones

Managing Director, entX Limited